CD Biosynsis delivers comprehensive Yeast Genome Editing & Metabolic Engineering Solutions to transform yeast, primarily Saccharomyces cerevisiae and Pichia pastoris, into highly efficient and robust microbial cell factories. Yeast systems are preferred for expressing complex eukaryotic proteins and producing high-value compounds due to their genetic tractability and capacity for post-translational modifications. Our integrated solutions cover the entire lifecycle of yeast engineering, from precise CRISPR/Cas-based genome editing and synthetic biology pathway construction to high-throughput screening and strain optimization for industrial scale-up. We accelerate the development of superior yeast strains for applications in pharmaceuticals, specialty chemicals, and sustainable bioproduction.
Get a QuoteYeast engineering is fundamental to modern synthetic biology and metabolic engineering, offering a unique blend of eukaryotic complexity and microbial scalability. Our solutions are designed to overcome key challenges in bioproduction, such as pathway bottlenecks, low tolerance to industrial conditions, and the need for complex protein modifications. We utilize a systematic Design-Build-Test-Learn (DBTL) approach powered by cutting-edge automation and computational analysis. This ensures that every genetic modification, from simple knockout to the integration of entire biosynthetic pathways, leads to quantifiable improvements in strain performance, guaranteeing commercially relevant yields and product quality.
Our integrated platform offers specialized services covering all aspects of yeast engineering:
Core Service Link
Service Focus
High-efficiency gene knockouts, precise gene integration (knock-in), point mutations, and large chromosomal modifications using CRISPR/Cas systems.
Core Service Link
Service Focus
Design, synthesis, and stable integration of de novo metabolic pathways, optimizing flux, and removing competing pathways for high-value compound production.
Core Service Link
Service Focus
Optimization of expression vectors, large-scale fermentation (Pichia and Saccharomyces), and multi-step chromatography for high-purity, functional eukaryotic proteins.
Core Service Link
Service Focus
Automated high-throughput screening (HTS), biosensors, and adaptive laboratory evolution (ALE) to rapidly improve strain titer, stability, and stress tolerance.
Core Service Link
Service Focus
Yeast Two-Hybrid (Y2H) assays, Flux Balance Analysis (FBA), and kinetic modeling to diagnose pathway issues and predict optimal genetic modifications.
Multiplex CRISPR/Cas Systems
Simultaneous editing of multiple genomic loci for rapid introduction of complex pathways or multiple host modifications.
Automated DBTL Platforms
Robotic liquid handling and high-throughput screening to cycle through Design, Build, Test, and Learn phases efficiently.
Computational Modeling & AI
Utilization of FBA, ML, and Bayesian Optimization to rationally guide strain design and predict superior genetic combinations.
Biopharmaceuticals
High-yield expression of therapeutic proteins, antibodies, and vaccine components with correct post-translational modifications.
Specialty Chemicals
Sustainable production of high-value natural products, terpenes, cannabinoids, flavors, and fragrances via engineered pathways.
Biofuels and Materials
Development of robust strains for efficient fermentation of second-generation feedstocks (xylose, cellulose) and bioplastic precursors.
Expertise Across Host Types
Extensive experience with both Saccharomyces and Pichia for versatile expression and production needs.
Rapid Strain Optimization
HTS and predictive modeling drastically reduce optimization time, delivering high-titer strains faster than manual methods.
Stable Genomic Integration
Focus on stable, marker-free chromosomal integration to ensure strain stability and meet industrial regulatory standards.
Full Data Transparency
Provision of comprehensive data packages, including genome sequencing confirmation and detailed performance metrics.
"The multiplex editing service allowed us to integrate three pathway genes simultaneously with high efficiency, significantly accelerating our early-stage pathway construction."
Dr. Samuel Liu, R&D Manager
"Their integrated metabolic engineering platform achieved a 65% increase in our target compound titer in just two optimization cycles, a truly impressive result."
Ms. Clara Dubois, Lead Bioengineer
"We received high-purity functional protein from their Pichia expression system, which met all our specifications for downstream structural analysis."
Mr. Ben Jacobs, CTO
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look forward to further working with them."
Dr. Raj Patel, Principal Investigator
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist
Which yeast strains do you commonly work with?
We primarily work with Saccharomyces cerevisiae (Bakers' Yeast) and Pichia pastoris (Methylotrophic Yeast), which are the most common industrial and research host organisms.
How do you ensure the stability of the engineered pathway?
We prioritize stable, marker-free integration of the entire pathway into the yeast chromosome, avoiding unstable plasmid-based systems which can be lost during large-scale fermentation.
What is the typical project timeline for a full metabolic engineering solution?
Timelines vary based on target complexity, but our DBTL approach, leveraging HTS and modeling, often shortens the typical 18-month timeline to 6-12 months for initial titer success.
What data is included in the final strain delivery package?
The package includes the final, confirmed yeast strain, full genome sequencing confirmation of the integrated pathway, detailed performance reports, and the optimized fermentation protocol.
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS, FDA).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.